Zoetis - ZTS Stock Forecast, Price & News

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. The Goldman Sachs Group decreased their price target on Zoetis from $208.00 to $202.00 and set a "buy" rating for the company in a research report on Thursday, July 21st. Stifel Nicolaus decreased their price target on Zoetis from $275.00 to $225.00 and set a "buy" rating for the company in a research report on Friday, June 24th. StockNews.com downgraded Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 26th. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research report on Friday, August 5th. Finally, Piper Sandler assumed coverage on Zoetis in a research report on Monday, July 11th. They set an "overweight" rating and a $205.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $224.14.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $174.06 on Thursday. The stock has a fifty day simple moving average of $171.81 and a two-hundred day simple moving average of $180.80. Zoetis has a 1-year low of $154.18 and a 1-year high of $249.27. The firm has a market cap of $81.48 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 2.98 and a beta of 0.73. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14.

Zoetis (NYSE:ZTS - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The company had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the previous year, the business earned $1.19 earnings per share. Zoetis's revenue was up 7.8% on a year-over-year basis. Analysts anticipate that Zoetis will post 5.01 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be issued a $0.325 dividend. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Wednesday, July 20th. Zoetis's payout ratio is currently 29.48%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 2,167 shares of the firm's stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares of the company's stock, valued at $4,269,818.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Roxanne Lagano sold 2,167 shares of Zoetis stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company's stock, valued at $4,269,818.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kristin C. Peck sold 9,689 shares of Zoetis stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The disclosure for this sale can be found here. Insiders sold 18,356 shares of company stock valued at $3,250,158 over the last three months. Company insiders own 0.12% of the company's stock.